

Benoit Rousseau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3158802/publications.pdf>

Version: 2024-02-01

83
papers

3,255
citations

236925

25
h-index

175258

52
g-index

95
all docs

95
docs citations

95
times ranked

4864
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	9.4	28
2	Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study. <i>European Journal of Cancer</i> , 2022, 168, 99-107.	2.8	3
3	High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE hypermutated colorectal cancers. <i>Molecular Oncology</i> , 2022, 16, 3055-3065.	4.6	0
4	PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	27.0	588
5	Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. <i>European Journal of Cancer</i> , 2021, 143, 55-63.	2.8	32
6	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. <i>Cancer Cell</i> , 2021, 39, 96-108.e6.	16.8	153
7	Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey. <i>Clinical Colorectal Cancer</i> , 2021, 20, 79-83.e4.	2.3	4
8	CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. <i>Cancer Discovery</i> , 2021, 11, 1844-1859.	9.4	37
9	The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. <i>New England Journal of Medicine</i> , 2021, 384, 1168-1170.	27.0	137
10	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. <i>Cell</i> , 2021, 184, 4032-4047.e31.	28.9	131
11	Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1686.	7.1	11
12	Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort. <i>Digestive and Liver Disease</i> , 2021, , .	0.9	0
13	Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PATients) cohort. <i>Journal of Geriatric Oncology</i> , 2020, 11, 586-592.	1.0	22
14	Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). <i>Oncologist</i> , 2020, 25, e266-e275.	3.7	3
15	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 295-303.e3.	1.9	12
16	Immune Therapy for Liver Cancers. <i>Cancers</i> , 2020, 12, 77.	3.7	49
17	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. <i>Targeted Oncology</i> , 2020, 15, 11-24.	3.6	65
18	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 147, 3177-3188.	5.1	17

#	ARTICLE	IF	CITATIONS
19	Evaluation of <i>POLE/POLD1</i> Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes. <i>JAMA Oncology</i> , 2020, 6, 589.	7.1	8
20	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	2.8	15
21	Clinical criteria predicting an overall survival benefit to platinum rechallenge (PR) in metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 490-490.	1.6	0
22	Impact of antibiotics (ATB) on the recurrence of resected colorectal cancer (CRC): Results of EVADER-1 a nation-wide pharmacoepidemiologic study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4106-4106.	1.6	1
23	Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , 2019, 51, 1357-1363.	0.9	80
24	Impact of the IDEA study on clinical practice for stage III colon cancer patients: A French GERCOR - FFCD - GI UNICANCER national survey. <i>Annals of Oncology</i> , 2019, 30, v210.	1.2	2
25	BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases. <i>British Journal of Surgery</i> , 2019, 106, 1237-1247.	0.3	33
26	<i>NF1</i> mutations identify molecular and clinical subtypes of lung adenocarcinomas. <i>Cancer Medicine</i> , 2019, 8, 4330-4337.	2.8	14
27	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106.	2.8	36
28	Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 1289-1291.	2.6	7
29	Characteristics of <i>BRAF</i> <i>V600E</i> Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. <i>Oncologist</i> , 2019, 24, e1331-e1340.	3.7	20
30	Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. , 2019, 7, 333.		129
31	RECIST and Choi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. <i>Cancer Imaging</i> , 2019, 19, 85.	2.8	9
32	Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with <i>de novo</i> carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 886-896.	5.1	22
33	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 58-65.	3.7	219
34	Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3121-3121.	1.6	1
35	Withholding anti-EGFR, the impact on outcome in RAS wild-type metastatic colorectal tumors (WAIT) Tj ETQq1 1 0,784314 rgBT /Ov	1.6	8
36	Guidelines and tumor boards are required for solid organ recipients with <i>de novo</i> carcinoma. <i>Oncotarget</i> , 2019, 10, 2789-2790.	1.8	1

#	ARTICLE	IF	CITATIONS
37	Abstract 91: Diet-variants and immune characterization of a stage-defined, transgenic immunocompetent mouse model of HCC (ASV-B). , 2019, , .		0
38	Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. Clinical and Translational Radiation Oncology, 2018, 10, 13-22.	1.7	18
39	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. , 2018, 181, 49-75.		9
40	Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient mismatch repair (pMMR) colorectal and endometrial cancers. Annals of Oncology, 2018, 29, viii34.	1.2	0
41	Withholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR) Tj ETQq1 1 0,784314,0gBT /Over	1.2	0
42	Metastatic colorectal signet-ring cell carcinoma: Clinical, histological and molecular description from an AGEO French multicenter retrospective cohort. Annals of Oncology, 2018, 29, viii186.	1.2	0
43	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations. Annals of Oncology, 2018, 29, viii261-viii262.	1.2	0
44	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients (Pts) with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations.. Journal of Clinical Oncology, 2018, 36, e16119-e16119.	1.6	0
45	Abstract 5511: Characterization of molecular and functional consequences of somaticNF1mutations in non-small cell lung cancers. , 2018, , .		0
46	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
47	Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2017, 142, 42-48.	2.8	34
48	Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. Critical Reviews in Oncology/Hematology, 2017, 113, 242-248.	4.4	68
49	Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Journal of the National Cancer Institute, 2017, 109, .	6.3	35
50	Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. Investigational New Drugs, 2017, 35, 79-86.	2.6	3
51	PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget, 2017, 8, 24644-24651.	1.8	146
52	Potential drug interactions in older patients with cancer: Updated data from the ELCAPA cohort survey. Annals of Oncology, 2017, 28, v557-v558.	1.2	1
53	Development and validation of a prognostic nomogram and score to predict overall survival and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, 354-354.	1.6	1
54	Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. Oncotarget, 2017, 8, 101383-101393.	1.8	31

#	ARTICLE	IF	CITATIONS
55	What Do Older Adults Know About Their Cancer Diagnosis and Treatment? The ELCAPA Cohort Study. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1360-1362.	2.6	6
56	<i>KRAS</i> oncogene in lung cancer: focus on molecularly driven clinical trials. <i>European Respiratory Review</i> , 2016, 25, 71-76.	7.1	72
57	First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 44-53.	4.4	25
58	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. <i>European Journal of Cancer</i> , 2016, 66, 75-82.	2.8	5
59	Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 191-192.	2.5	12
60	Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. <i>Hepatology</i> , 2016, 64, 2038-2046.	7.3	343
61	Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion. <i>Medicine (United States)</i> , 2016, 95, e4006.	1.0	3
62	Acquired Type II von Willebrand Syndrome in Locally Advanced Bladder Cancer Successfully Treated With Intravenous Immunoglobulin and Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e95-e97.	1.9	3
63	Platinum rechallenge in patients with advanced biliary tract carcinoma (ABTC) after failure of gemcitabine (GEM)-platinum combination: A national AGEO retrospective study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4076-4076.	1.6	0
64	Multimodal treatment choice and feasibility in older patients with resectable gastric cancer: a multicentric cohort study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15528-e15528.	1.6	0
65	1549 Blood alcohol level in patients treated with gemcitabine and taxanes. <i>European Journal of Cancer</i> , 2015, 51, S220-S221.	2.8	0
66	RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. <i>British Journal of Cancer</i> , 2015, 113, 1313-1322.	6.4	19
67	Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2484-2485.	1.6	6
68	Weekly paclitaxel versus ADT alone in localized high-risk prostate cancer: Results of a single-institution phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 37-37.	1.6	1
69	Abstract P5-15-12: Clinico-biological characteristics of patients surviving more than two years with metastatic breast cancer (MBC): Results of a transversal national multicentric survey. , 2015, , .		0
70	Relationship between response and progression free survival in 8965 patients with advanced renal cell carcinoma treated with first-line antiangiogenic therapy in 39 trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15581-e15581.	1.6	0
71	Blood alcohol level in patients treated with gemcitabine and taxanes.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17664-e17664.	1.6	0
72	First line antiangiogenics for advanced renal cell carcinoma: A systematic review and network meta-analysis comparing efficacy and toxicities.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15586-e15586.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Sorafenib discontinuation due to toxicity: A literature-based meta-analysis and meta-regression analysis of 18 randomized controlled trials in solid and hematologic malignancies.. Journal of Clinical Oncology, 2014, 32, e13545-e13545.	1.6	0
74	Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. European Heart Journal, 2013, 34, 570-577.	2.2	145
75	Is there a withdrawal syndrome with abiraterone acetate (AA)?. Journal of Clinical Oncology, 2013, 31, 89-89.	1.6	8
76	Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Annals of Oncology, 2012, 23, 450-457.	1.2	67
77	Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Investigational New Drugs, 2012, 30, 2046-2049.	2.6	95
78	MÃ©canismes de rÃ©sistances aux inhibiteurs de RAF : revue de la littÃ©rature. Oncologie, 2012, 14, 2-4.	0.7	2
79	FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World Journal of Gastroenterology, 2012, 18, 4533.	3.3	41
80	REVIEW OF 433 PATIENTS HIHGHLY OVEREXPOSED DURING RADIOTHERAPY FOR PROSTATE CANCER. Radiotherapy and Oncology, 2011, 98, S42-S43.	0.6	0
81	FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients.. Journal of Clinical Oncology, 2011, 29, 272-272.	1.6	2
82	Stage II and Stage III Colon Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 202-209.	2.0	39
83	Alternative <i>Neisseria</i> spp. type IV pilin glycosylation with a glyceramido acetamido trideoxyhexose residue. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14783-14788.	7.1	77